
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **March 9, 2018**

Arsanis, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-38295
(Commission
File Number)

27-3181608
(IRS Employer
Identification No.)

890 Winter Street, Suite 230
Waltham, Massachusetts
(Address of principal executive offices)

02451
(Zip Code)

Registrant's telephone number, including area code: **(781) 819-5704**

Not applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition

On March 9, 2018, Arsanis, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2017. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release issued by the Company on March 9, 2018

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ARSANIS, INC.

Date: March 9, 2018

By: /s/ René Russo
René Russo
President and Chief Executive Officer

Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017

Commenced Phase 2 trial of lead program ASN100
Completed initial public offering and concurrent private placement
Completed Series D financing supported by major healthcare investors
Initiated ASN500 RSV program supported by the Bill & Melinda Gates Foundation

WALTHAM, Mass. and VIENNA, Austria (Business Wire) – March 9, 2018 – Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2017.

“2017 was a transformative year for Arsanis, with significant clinical, financial and staffing achievements that position us well as we advance our novel monoclonal antibody-based therapies to address serious infections,” said René Russo, chief executive officer of Arsanis. “We are pleased with the continued progress of our Phase 2 clinical study of ASN100, which we believe represents a novel approach to managing the clinical and health economic burden of pneumonia in critically ill hospital patients. We expect to report results of an interim analysis from this study in the first half of this year and top-line efficacy results from the completion of this trial in the second half of 2018.”

ASN100, Arsanis’ lead product candidate, is a first-in-class mAb therapy that neutralizes the six cytotoxins critical to *Staphylococcus aureus* pneumonia pathogenesis, and is currently being evaluated in a Phase 2 clinical trial for the prevention of *S. aureus* pneumonia in high-risk, mechanically ventilated patients. Arsanis believes ASN100 has both preventive and therapeutic potential in this setting and may reduce the need for multiple antibiotic courses that contribute to antibiotic resistance, toxicity, and subsequent infections. The company believes infection prevention in this population would also reduce mechanical ventilation days, shorten hospital stays, reduce healthcare costs, and decrease the risk of re-hospitalization.

Dr. Russo continued, “We also are making progress in other areas, including the advancement of our ASN500 program, which currently focuses on evaluating multiple highly potent monoclonal antibodies that target respiratory syncytial virus, or RSV. We expect to select a lead mAb for development from this program in the near term and to begin preclinical testing to advance this candidate toward clinical development.”

“Our completion of an initial public offering and concurrent private placement of common stock in November 2017 combined with our April 2017 Series D financing provide us with adequate capital to fund our planned operations into the second half of 2019, well beyond our anticipated timelines for the Phase 2 data from our lead ASN100 program,” said Michael Gray, chief operating and chief financial officer of Arsanis. “Our ASN500 program is currently funded under a grant agreement with the Bill & Melinda Gates Foundation, and we therefore expect that the majority of our available capital will continue to be directed toward advancement of ASN100.”

Key 2017 highlights

- Advanced the Phase 2 clinical trial of ASN100 to evaluate the safety, tolerability, and efficacy of a single dose of ASN100 versus placebo for the prevention of *Staphylococcus aureus* pneumonia in high-risk, mechanically ventilated patients.
 - Secured an exclusive worldwide license to antibodies targeting RSV from Adimab and entered into a grant agreement of up to \$9.3 million from the Bill & Melinda Gates Foundation to fund preclinical development activities.
 - Closed on a \$50.5 million Series D financing led by the Bill & Melinda Gates Foundation, with strong support from existing investors.
-

- Presented preclinical and Phase 1 clinical data supportive of ASN100's non-antibiotic mechanism of action, safety and pharmacokinetics.
- Appointed senior pharmaceutical executives Chip Clark and David McGirr to our Board of Directors and promoted Michael Gray to Chief Operating Officer and Chief Financial Officer.
- Closed the company's initial public offering of 4,600,000 shares and a concurrent private placement of 2,000,000 shares of its common stock at a public offering price of \$10.00 per share, including 600,000 additional shares of common stock issued upon the exercise in full by the underwriters of their over-allotment option. The gross proceeds to Arsanis from these two offerings were \$66.0 million, before deducting underwriting discounts and commissions and other offering expenses.

Upcoming Activities

Arsanis expects that it will make presentations at the following conferences through April 2018:

- Presentation at the 38th Annual Cowen and Company Health Care Conference on March 12, 2018 in Boston, MA
- Presentation at the Needham & Company 17th Annual Healthcare Conference on March 27, 2018 in New York City
- Multiple presentations at the 28th European Congress of Clinical Microbiology and Infectious Diseases from April 21-24, 2018, in Madrid, Spain

Fourth Quarter 2017 Financial Results

For the fourth quarter ended December 31, 2017, Arsanis reported a net loss of \$11.2 million, or \$1.68 loss per share, as compared to a net loss of \$5.3 million and \$10.37 loss per share for the fourth quarter of 2016.

Operating expenses for the fourth quarter of 2017 were \$11.6 million, as compared to \$5.7 million for the fourth quarter of 2016, and were comprised of the following:

Research and development expenses were \$9.2 million for the fourth quarter of 2017, as compared to \$4.2 million for the fourth quarter of 2016. The increase of \$5.0 million was primarily due to an increase of \$4.2 million in direct costs for our ASN100 program, an increase of \$0.3 million in direct costs for our ASN500 program, and an increase of \$0.6 million in unallocated research and development expenses.

General and administrative expenses were \$2.4 million for the fourth quarter of 2017, as compared to \$1.5 million for the fourth quarter of 2016. The increase of \$0.9 million was primarily due to an increase of \$0.2 million in personnel-related costs and an increase of \$0.6 million in professional fees.

Other income, net was \$0.4 million for each of the quarters ended December 31, 2017 and 2016.

As of December 31, 2017, Arsanis's cash, cash equivalents, marketable securities and investments totaled \$76.8 million with approximately 14.29 million shares of common stock outstanding.

Full Year 2017 Financial Results

For the year ended December 31, 2017, Arsanis reported a net loss of \$33.9 million, or \$16.45 loss per share on both a basic and diluted basis, as compared to a net loss of \$23.0 million, or \$44.79 loss per share on both a basic and diluted basis in 2016.

Operating expenses were \$36.1 million for the year ended December 31, 2017, as compared to \$24.3 million for the same period in 2016, and were comprised of the following:

Research and development expenses were \$28.1 million for the year ended December 31, 2017, as compared to \$17.8 million for the year ended December 31, 2016. The increase of \$10.3 million was primarily due to an increase of \$9.3 million in direct development costs for the ASN100 program and an increase of \$0.9 million in direct costs for the company's ASN500 program.

General and administrative expenses were \$8.0 million for the year ended December 31, 2017, as compared to \$6.5 million for the year ended December 31, 2016. The increase of \$1.5 million was primarily due to a full year of expenses from the 2016 hiring of general and administrative functions to support the build-out of Arsanis' U.S. headquarter operations, as well as an increase in professional fees due to costs primarily related to legal, audit and consulting services associated with becoming a public company.

Other income, net was \$2.3 million for the year ended December 31, 2017, as compared to \$1.4 million for the year ended December 31, 2016.

About Arsanis

Arsanis, Inc. is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build and advance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets. The Company's lead clinical program, ASN100, is aimed at serious *Staphylococcus aureus* infections and is being evaluated in a Phase 2 clinical trial for the prevention of *S. aureus* pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.

Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).

For more information, please visit the Arsanis website at www.arsanis.com.

ARSANIS, INC.
CONSOLIDATED BALANCE SHEETS
(unaudited)
(In thousands)

	December 31, 2017	December 31, 2016
Assets		
Cash and cash equivalents	\$ 76,793	\$ 3,035
Restricted cash	355	394
Grant and incentive receivables	1,608	1,345
Property and equipment, net	421	519
Prepaid expenses and other assets	2,077	2,311
Total assets	<u>\$ 81,254</u>	<u>\$ 7,604</u>
Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)		
Accounts payable, accrued expenses and other liabilities	\$ 7,681	3,888
Unearned income	2,630	2,558
Loans payable, net of discount	12,236	12,426
Convertible promissory notes, net of discount	-	2,863
Derivative liability	-	2,593
Total liabilities	<u>22,547</u>	<u>24,328</u>
Redeemable convertible preferred stock	-	39,838
Stockholders' equity (deficit)	<u>58,707</u>	<u>(56,562)</u>
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	<u>\$ 81,254</u>	<u>\$ 7,604</u>

ARSANIS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(In thousands, except share and per share data)

	Three months ended December 31,		Year ended December 31,	
	2017	2016	2017	2016
Operating expenses				
Research and development	\$ 9,230	\$ 4,227	\$ 28,128	\$ 17,831
General and administrative	2,376	1,473	8,005	6,515
Total operating expenses	<u>11,606</u>	<u>5,700</u>	<u>36,133</u>	<u>24,346</u>
Loss from operations	(11,606)	(5,700)	(36,133)	(24,346)
Grant and incentive income	688	561	3,868	2,390
Interest expense	(363)	(792)	(2,079)	(2,515)
Interest income	214	-	214	-
Change in fair value of warrant liability	(47)	28	(31)	39
Change in fair value of derivative liability	-	566	762	1,388
Loss on extinguishment of debt	-	-	(462)	(35)
Other income (expense), net	(73)	16	(16)	104
Total other income (expense), net	<u>419</u>	<u>379</u>	<u>2,256</u>	<u>1,371</u>
Net loss	(11,187)	(5,321)	(33,877)	(22,975)
Accretion of redeemable convertible preferred stock to redemption value	(8)	(6)	(44)	(25)
Net loss attributable to common stockholders	<u>\$ (11,195)</u>	<u>\$ (5,327)</u>	<u>\$ (33,921)</u>	<u>\$ (23,000)</u>
Net loss per share attributable to common stockholders, basic and diluted	<u>\$ (1.68)</u>	<u>\$ (10.37)</u>	<u>\$ (16.45)</u>	<u>\$ (44.79)</u>
Weighted-average common shares outstanding, basic and diluted	<u>6,655,202</u>	<u>513,900</u>	<u>2,061,845</u>	<u>513,527</u>

Cautionary note on forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development and regulatory status of our product candidates, the timing and conduct of clinical trials and preclinical studies, the potential application of any of the Company's product candidates in any other indications and our estimate of the period in which we expect to have cash to fund our planned operations. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of important factors, including, but not limited to: uncertainties inherent in the availability and timing of data from ongoing clinical trials, expectations for regulatory approvals to conduct clinical trials, the availability of cash resources and need for additional financing or other actions and other important risk factors as set forth in filings that we periodically make with the U.S. Securities Exchange Commission, or SEC. The forward-looking statements contained in this press release reflect the current views of Arsanis, Inc. with respect to future events, and we assume no obligation to update any forward-looking statements except as required by applicable law.

###

Media Contact:

Ten Bridge Communications
Krystle Gibbs, 508-479-6358
krystle@tenbridgecommunications.com

Investor Contact:

Michael Gray, 781-819-5201
Chief Operating and Chief Financial Officer
mike.gray@arsanis.com